These data prove that the administration of SGLT-2 inhibitors has protective effects, opposed to almost all the pathophysiological mechanisms that insulin resistance generates in patients with T2DM [84], and serves as a useful therapy in clinical practice. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.